Stemline Therapeutics
  • Home
  • About Us
    • Management
    • Business Development
  • Product Pipeline
    • Scientific Presentations
    • Clinical Trials
  • Expanded Access
  • News & Media
  • Contact Us
    • Reporting Concerns
  • BPDCN

SL-101, a Novel Monoclonal Antibody-Conjugate That Targets Interleukin-3 Receptor Alpha (CD123), Possesses Preclinical Anti-Tumor Activity Against Hodgkin's Lymphoma

SL-101, A Novel Monoclonal Antibody-Conjugate That Targets Interleukin-3…


by srs_admin

SL-401, A Targeted Therapy Directed to the Interleukin-3 Receptor Present On Leukemia Blasts and Cancer Stem Cells, Is Active As a Single Agent in Patients with Advanced AML. ASH 2012.

SL-401, A Targeted Therapy Directed to the Interleukin-3 Receptor Present On…


by srs_admin

A Pilot Study of Peptide-Based Vaccines in Combination With Poly ICLC in Patients With WHO Grade 2 Low-Grade Glioma

A pilot study of peptide-based vaccines in combination with poly ICLC in…


by srs_admin

The IL-3Rα-Targeted Drug SL-401 Selectively Kills Blastic Plasmacytoid Dendritic Cell Neoplasm Cells. ASH 2011.

The IL-3Rα-Targeted Drug SL-401 Selectively Kills Blastic Plasmacytoid…


by srs_admin

Hodgkin's Lymphoma Cell Lines Have Up-Regulated IL-3 Receptor α (IL-3Rα) Expression and Are Sensitive to SL-401, an IL-3Rα-Targeted Drug

Hodgkin’s Lymphoma Cell Lines Have Up-regulated IL-3 Receptor α (IL-3Rα)…


by srs_admin

Phase I/II Vaccine Study Targeting Novel HLA-A2-Restricted CTL Epitopes in Combination With Poly-ICLC in Patients With Recurrent Malignant Glioma

Phase I/II vaccine study targeting novel HLA-A2-restricted CTL epitopes in…


by srs_admin

  • 1
  • …
  • 5
  • 6
  • 7
  • About Us
    • Management
    • Business Development
  • Product Pipeline
    • Scientific Presentations
    • Clinical Trials
  • Contact Us
  • News & Media
  • BPDCN
logo

© – Stemline Therapeutics, Inc. All rights reserved | Privacy & Terms of Use | CCPA Policy | Cookie Policy | Privacy Notice for Social Network Users & Netiquette |

logo

Stemline Therapeutics is a society of the Menarini Group

Privacy Preference Center

Privacy Preferences